ADRIAN M. DI BISCEGLIE, M.D.; VINOD K. RUSTGI, M.D.; JAY H. HOOFNAGLE, M.D.; GEOFFREY M. DUSHEIKO, M.D.; MICHAEL T. LOTZE, M.D.
Hepatocellular carcinoma is the most frequent cancer worldwide, responsible for approximately 1 000 000 deaths annually, most of them in the Far East and in sub-Saharan Africa. It usually presents at an advanced stage and has a poor prognosis. There is strong evidence of an etiologic role for hepatitis B virus infection in the etiology of hepatocellular carcinoma. Carriers of the virus are 94 times more at risk for hepatocellular carcinoma than noncarriers. In many cases hepatitis B virus DNA is integrated within the cellular genome of the tumor. Programs have been established to detect hepatocellular carcinoma at an early stage; persons at high risk are regularly screened by measurement of serum alpha-fetoprotein levels and ultrasound examination of the liver. Surgical resection offers the only hope of cure at present, as chemotherapy, radiotherapy, and immunotherapy have not shown promise. Ideally, surgery should be done on small asymptomatic tumors.
DI BISCEGLIE AM, RUSTGI VK, HOOFNAGLE JH, DUSHEIKO GM, LOTZE MT. Hepatocellular Carcinoma. Ann Intern Med. ;108:390–401. doi: 10.7326/0003-4819-108-3-390
Download citation file:
Published: Ann Intern Med. 1988;108(3):390-401.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use